By Annalee Armstrong
CureVac’s so-called first generation COVID vaccine—a shot that failed to reach anywhere near the high efficacy bar set by rivals—is continuing to drag on the German biotech’s earnings, a break in the sails expected to stay around through the year.
read more
By Dave Muoio
Plaintiffs alleged the 27-hospital nonprofit used its size to suppress competition and drive "unreasonably high prices" for payers, employers and taxpayers.
read more
By Andrea Park
Using PrecisionOS’ technology—which is installed on Oculus VR headsets—surgeons and OR technicians will be able to complete practice sessions using Siemens' Cios Spin machine together, giving them the chance to share their expertise with one another and improve their collaboration in the operating room.
read more
By Max Bayer
Forte Biosciences’ top shareholder is calling on the biotech to close up shop before it pours money into a brand new lead asset, saying the compound appears to have come “out of thin air.”
read more
By Robert King
A new bipartisan bill aims to rein in several pharmacy benefit manager practices ranging from spread pricing to pharmacy clawback fees.
read more
By Fraiser Kansteiner
The Securities and Exchange Commission has charged California-based executive compensation consultant Frank Glassner with insider trading, according to a complaint filed in a federal Manhattan court Tuesday. Glassner was a long-time consultant to Kadmon who was enlisted to provide acquisition-related services to the biotech, the SEC said in a release. Sanofi closed its $1.9 billion deal for the biotech in November.
read more
By Andrea Park
RapidAI's software is designed to speed up the time it takes for physicians to identify a pulmonary embolism, confirm the diagnosis and begin treatment while also helping hospitals coordinate care and allot resources more efficiently.
read more
By Heather Landi
Regional health system Geisinger tapped Amazon's cloud division as its strategic cloud tech provider and plans to transition its entire digital portfolio of more than 400 applications and numerous workflows to AWS.
read more
By Zoey Becker
Teva and Allergan forked over $161 million to West Virginia to settle opioid litigation, including $27 million worth of Narcan.
read more
By Conor Hale
The company claims its tech can simultaneously analyze DNA, RNA and methylation structures as well as the sample’s overall protein content.
read more
By Nick Paul Taylor
Antios Therapeutics’ push to develop a curative hepatitis B therapy has hit turbulence. The FDA has hit Antios with a clinical hold over a safety report, prompting Assembly Biosciences to terminate its clinical trial collaboration agreement with the deep-pocketed biotech.
read more
